DK3519050T3 - Sammensætninger til behandling af oftalmiske sygdomme - Google Patents

Sammensætninger til behandling af oftalmiske sygdomme Download PDF

Info

Publication number
DK3519050T3
DK3519050T3 DK17857434.9T DK17857434T DK3519050T3 DK 3519050 T3 DK3519050 T3 DK 3519050T3 DK 17857434 T DK17857434 T DK 17857434T DK 3519050 T3 DK3519050 T3 DK 3519050T3
Authority
DK
Denmark
Prior art keywords
compositions
treatment
ophthalmic diseases
ophthalmic
diseases
Prior art date
Application number
DK17857434.9T
Other languages
English (en)
Inventor
Basil Rigas
Original Assignee
Medicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicon Pharmaceuticals Inc filed Critical Medicon Pharmaceuticals Inc
Priority claimed from PCT/US2017/054051 external-priority patent/WO2018064354A1/en
Application granted granted Critical
Publication of DK3519050T3 publication Critical patent/DK3519050T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17857434.9T 2016-09-28 2017-09-28 Sammensætninger til behandling af oftalmiske sygdomme DK3519050T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662400955P 2016-09-28 2016-09-28
PCT/US2017/054051 WO2018064354A1 (en) 2016-09-28 2017-09-28 Compositions and methods for treating ophthalmic conditions

Publications (1)

Publication Number Publication Date
DK3519050T3 true DK3519050T3 (da) 2023-07-24

Family

ID=67106173

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17857434.9T DK3519050T3 (da) 2016-09-28 2017-09-28 Sammensætninger til behandling af oftalmiske sygdomme

Country Status (13)

Country Link
EP (2) EP3519050B1 (da)
CN (1) CN110290835B (da)
DK (1) DK3519050T3 (da)
ES (1) ES2951077T3 (da)
FI (1) FI3519050T3 (da)
HR (1) HRP20230634T1 (da)
HU (1) HUE062406T2 (da)
LT (1) LT3519050T (da)
PL (1) PL3519050T3 (da)
PT (1) PT3519050T (da)
RS (1) RS64399B1 (da)
SI (1) SI3519050T1 (da)
SM (1) SMT202300229T1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102250775B1 (ko) * 2019-10-18 2021-05-11 주식회사 에스알파테라퓨틱스 근시 치료를 위한 디지털 장치 및 애플리케이션
CN112274106B (zh) * 2020-06-23 2025-02-11 重庆康华瑞明科技股份有限公司 一种干眼检查装置的电动收放机构和电动调节机构
CN118615239B (zh) * 2024-06-17 2025-07-22 明思未来(北京)科技发展有限公司 一种依维莫司眼局部给药制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
CN1976692B (zh) * 2004-06-23 2011-05-25 矫正诊疗公司 用视黄基衍生物治疗眼部疾病的方法和组合物
US20070299124A1 (en) * 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
WO2009023631A1 (en) 2007-08-10 2009-02-19 Basil Rigas Anti-inflammatory compounds and uses thereof
US20120295979A1 (en) * 2011-05-03 2012-11-22 Florida Atlantic University Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress
WO2013130625A1 (en) 2012-02-27 2013-09-06 Basil Rigas Phospho-ester derivatives and uses thereof
CA2885740A1 (en) 2012-09-21 2014-03-27 Basil Rigas Compounds and compositions for use in the prevention and treatment of inflammation-related disorders, pain and fever, skin disorders, cancer and precancerous conditions thereof

Also Published As

Publication number Publication date
FI3519050T3 (fi) 2023-07-27
CN110290835B (zh) 2023-03-07
EP4272761A3 (en) 2024-01-03
HRP20230634T1 (hr) 2023-10-13
EP3519050A4 (en) 2020-06-17
PT3519050T (pt) 2023-08-31
PL3519050T3 (pl) 2023-10-09
EP3519050A1 (en) 2019-08-07
EP3519050B1 (en) 2023-06-07
EP4272761A2 (en) 2023-11-08
LT3519050T (lt) 2023-08-25
SMT202300229T1 (it) 2023-09-06
ES2951077T3 (es) 2023-10-17
CN110290835A (zh) 2019-09-27
HUE062406T2 (hu) 2023-10-28
RS64399B1 (sr) 2023-08-31
SI3519050T1 (sl) 2023-10-30

Similar Documents

Publication Publication Date Title
DK3728271T3 (da) Makrocykliske forbindelser til behandling af sygdomme
DK3501542T3 (da) Esketamin til behandling af depression
DK3326641T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3399962T3 (da) Oftalmisk sammensætning til behandling af tør øjensygdom
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3548061T3 (da) Behandling af neurologiske sygdomme
DK3210973T3 (da) Heteroarylforbindelser til behandling af oftalmiske sygdomme
DK3258919T3 (da) Næsepulverformulering til behandling af hypoglykæmi
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
DK3578562T3 (da) L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
DK3612208T5 (da) Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3638293T5 (da) Sammensætninger til behandling af cancer
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3452093T3 (da) Ophthalmiske sammensætninger